Transformational Late Stage Drugs Delivered Through Deal-Making

Today's biopharma industry has a richer and more exciting late stage pipeline of compelling new therapeutics than its had in years, drawing lots of enthusiasm from analysts and investors. Goldman Sachs (GS) recently published a report on the "10 drugs that could transform the industry" (Jan 2014), highlighting how many of these drugs have "game-changing commercial potential", and that these drugs will help the industry "move beyond the cliff" of patent expiries. The GS healthcare team has put th...